On the basis of type, the global breast imaging market is segmented into two major categories, namely, ionizing technologies and non-ionizing technologies. Ionizing technologies are further segmented into eight subsegments, namely, analog mammography, full-field digital mammography (FFDM), 3D breast tomosynthesis, positron emission tomography/computed tomography (PET/CT), molecular breast-specific gamma imaging (MBI/BSGI), cone-beam computed tomography (CBCT), positron emission mammography (PEM), and electric impedance tomography. The 3D breast tomosynthesis segment is expected to grow at the highest CAGR in the next five years, owing to the increasing regulatory approvals for 3D breast tomosythesis systems, benefits offered by these systems over other technologies, and higher patient accessibility offered by these systems.

The non-ionizing breast imaging technologies segment is classified into five subsegments, namely, breast MRI, breast ultrasound, automated whole breast ultrasound (AWBU), breast thermography, and optical imaging. The automated whole-breast ultrasound (AWBU) segment is expected to grow at the highest CAGR in the next five years, owing to benefits such as high reproducibility, high resolution power with 3D capability, lower false positives, and faster imaging.

This report studies the breast imaging market over the forecast period of 2016 to 2021. The market is expected to reach USD 4.14 Billion by 2021, at a CAGR of 8.5% from 2016 to 2021. A number of factors such as rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues are driving the growth of the global breast imaging market. However, high installation cost of breast imaging systems, side effects of radiation exposure, and errors in breast cancer screening and diagnosis are some of the major factors restraining the growth of this market. In addition, stringent regulatory approval procedures and unfavorable reimbursement scenario in developing countries are expected to further restrain the growth of this market in the coming years.

The breast imaging market is segmented into four major regional segments, namely, North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is estimated to dominate the global breast imaging market, majorly due to the rising incidence of breast cancer, favorable reimbursement scenario, ongoing technological advancements by market players, implementation of new breast density notification law in the U.S., rapid growth in geriatric population, and growing demand for the use of low levels or negligible radiation doses in the region. On the other hand, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. The high growth in this market can majorly be attributed to the rising patient population, increasing healthcare expenditure, higher government spending on breast cancer research studies, and implementation of several programs focused on creating awareness about the early detection of breast cancer.

Product launches, upgrades, and approvals form the key growth strategies adopted by major players operating in the global breast imaging market. Moreover, a large number of players are focusing on growth strategies such as partnerships, agreements, and collaborations to strengthen their product portfolios and expand their geographic presence in the global breast imaging market.

Hologic, Inc. (U.S.), GE Healthcare (U.K.), Siemens Healthcare (Germany), Philips Healthcare (Netherlands), Fujifilm Holdings Corporation (Japan), Gamma Medica, Inc. (U.S.), Toshiba Corporation (Japan), Sonocine, Inc. (U.S.), Aurora Imaging Technology, Inc. (U.S.), and Dilon Technologies, Inc. (U.S.) are some of the key players operating in the global breast imaging market.

More Info: https://www.marketsandmarkets.com/Market-Reports/breast-imaging-technologies-market-897.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]